Anti-tumor Effects of MiR-34a by Regulating Immune Cells in the Tumor Microenvironment

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Mar 23

PMID 36951490

Authors

Man Yin

Zhiqiang Zhang

Yunfei Wang

Affiliations

Soon will be listed here.

Abstract

Malignant tumors pose a serious threat to human health. The development of malignant tumors is characterized by uncontrolled cell division and immune evasion. The micro-ribonucleic acid-34a (miR-34a) is a small noncoding single-stranded ribonucleic acid that is ubiquitously present in normal human tissues. However, it has been confirmed to be dysregulated in a variety of tumor cells. Numerous research have revealed the importance of miR-34a in the treatment of various malignancies. MiR-34a deletion can hasten the growth of tumors whereas miR-34a overexpression suppresses the proliferation, invasion, and migration of cancer cells. Moreover, more recent studies have highlighted its role in immunity and investigated its applicability to particular tumors. Through various immune cells, factors, and other mechanisms, miR-34a can inhibit tumor carcinogenesis. In view of the important role of miR-34a in tumors, this research reviewed the aspects of miR-34a regulation of tumor immune microenvironment to exert anti-tumor effects in order to clarify the potential immunotherapy value of miR-34a in tumors.

Citing Articles

Mechanisms and technologies in cancer epigenetics.

Sherif Z, Ogunwobi O, Ressom H Front Oncol. 2025; 14:1513654.

PMID: 39839798 PMC: 11746123. DOI: 10.3389/fonc.2024.1513654.

Revolutionizing cancer therapy: nanoformulation of miRNA-34 - enhancing delivery and efficacy for various cancer immunotherapies: a review.

Fawzy M, Hassan H, Sedky N, Nafie M, Youness R, Fahmy S Nanoscale Adv. 2024; .

PMID: 39309515 PMC: 11414826. DOI: 10.1039/d4na00488d.

Understanding the role of miRNAs in cervical cancer pathogenesis and therapeutic responses.

Chauhan P, Pramodh S, Hussain A, Elsori D, Lakhanpal S, Kumar R Front Cell Dev Biol. 2024; 12:1397945.

PMID: 39263322 PMC: 11387185. DOI: 10.3389/fcell.2024.1397945.

Diagnostic value of miR-34a in Mycoplasma pneumoniae pneumonia in children and its correlation with rehabilitation effect.

Li M, Lu L, Xu H J Cardiothorac Surg. 2024; 19(1):507.

PMID: 39223566 PMC: 11367975. DOI: 10.1186/s13019-024-02992-5.

Anti-tumor effects of miR-34a by regulating immune cells in the tumor microenvironment.

Yin M, Zhang Z, Wang Y Cancer Med. 2023; 12(10):11602-11610.

PMID: 36951490 PMC: 10242310. DOI: 10.1002/cam4.5826.

References

Wang X, Chang X, Zhuo G, Sun M, Yin K . Twist and miR-34a are involved in the generation of tumor-educated myeloid-derived suppressor cells. Int J Mol Sci. 2013; 14(10):20459-77. PMC: 3821625. DOI: 10.3390/ijms141020459. View

Gabrilovich D, Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74. PMC: 2828349. DOI: 10.1038/nri2506. View

Liu Y, Jiang J, Liu C, Zhao W, Ma Y, Zheng Z . Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma. Am J Transl Res. 2021; 13(3):988-1005. PMC: 8014418. View

Wang X, Wang H, McCoy J, Banerjee N, Rader J, Broker T . Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA. 2009; 15(4):637-47. PMC: 2661824. DOI: 10.1261/rna.1442309. View

Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D . miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene. 2012; 32(9):1155-63. PMC: 4085050. DOI: 10.1038/onc.2012.132. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Faghihloo E, Araei Y, Mohammadi M, Mirzaei H, Mohammadi H, Mokhtari-Azad T . The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line. Cancer Gene Ther. 2016; 23(11):396-399. DOI: 10.1038/cgt.2016.52. View

Garzon R, Marcucci G, Croce C . Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10):775-89. PMC: 3904431. DOI: 10.1038/nrd3179. View

Glantz S, Gonzalez M . Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet. 2011; 379(9822):1269-71. PMC: 3260384. DOI: 10.1016/S0140-6736(11)60615-6. View

10.

Xiao X, Huang X, Ye F, Chen B, Song C, Wen J . The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Sci Rep. 2016; 6:21735. PMC: 4763192. DOI: 10.1038/srep21735. View

11.

Chen C, Bai L, Cao F, Wang S, He H, Song M . Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis. Oncogene. 2019; 38(23):4527-4539. DOI: 10.1038/s41388-019-0735-4. View

12.

Jamali L, Tofigh R, Tutunchi S, Panahi G, Borhani F, Akhavan S . Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J Cell Physiol. 2018; 233(11):8538-8550. DOI: 10.1002/jcp.26850. View

13.

Enwere E, Kornaga E, Dean M, Koulis T, Phan T, Kalantarian M . Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017; 30(4):577-586. DOI: 10.1038/modpathol.2016.221. View

14.

Kim V, Han J, Siomi M . Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009; 10(2):126-39. DOI: 10.1038/nrm2632. View

15.

Brawner K, Morrow C, Smith P . Gastric microbiome and gastric cancer. Cancer J. 2014; 20(3):211-6. PMC: 4149312. DOI: 10.1097/PPO.0000000000000043. View

16.

Hsu H, Choy C, Kasiappan R, Shih H, Sawyer J, Shu C . MCT-1 oncogene downregulates p53 and destabilizes genome structure in the response to DNA double-strand damage. DNA Repair (Amst). 2007; 6(9):1319-32. DOI: 10.1016/j.dnarep.2007.02.028. View

17.

Wang P, Zhai G, Bai Y . Values of miR-34a and miR-218 expression in the diagnosis of cervical cancer and the prediction of prognosis. Oncol Lett. 2018; 15(3):3580-3585. PMC: 5795828. DOI: 10.3892/ol.2018.7791. View

18.

Yang P, Li Q, Feng Y, Zhang Y, Markowitz G, Ning S . TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012; 22(3):291-303. PMC: 3443566. DOI: 10.1016/j.ccr.2012.07.023. View

19.

Naeli P, Pourhanifeh M, Karimzadeh M, Shabaninejad Z, Movahedpour A, Tarrahimofrad H . Circular RNAs and gastrointestinal cancers: Epigenetic regulators with a prognostic and therapeutic role. Crit Rev Oncol Hematol. 2019; 145:102854. PMC: 6982584. DOI: 10.1016/j.critrevonc.2019.102854. View

20.

Rokavec M, Li H, Jiang L, Hermeking H . The p53/miR-34 axis in development and disease. J Mol Cell Biol. 2014; 6(3):214-30. DOI: 10.1093/jmcb/mju003. View